Learn More >

Ministry Status: Activation Status

Ontario Public Drug Programs

Executive Officer Communications

Date Title
2021
July 5

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date July 5, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date July 5, 2021)
    – Updated: Questions and Answers for Pharmacists
    – Updated: Questions and Answers for Patients

June 25

*Please refer to entry posted on July 5, 2021 for the latest updated EO Notice on Eligibility + Billing that was effective on July 5, 2021.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date June 25, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date June 25, 2021)
    – Updated: Questions and Answers for Pharmacists
    – Updated: Questions and Answers for Patients

June 17

*Please refer to entry posted on July 5, 2021 for the latest updated EO Notice on Eligibility + Billing that was effective on July 5, 2021.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date June 17, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
    – Updated: Questions and Answers for Pharmacists
    – Updated: Questions and Answers for Patients

June 14

*Please refer to entry posted on July 5, 2021 for the latest updated EO Notice on Eligibility + Billing that was effective on July 5, 2021.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date June 14, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date June 14, 2021)
    – Updated: Questions and Answers for Pharmacists
    – Updated: Questions and Answers for Patients

June 14 Executive Officer Notice: Improved Access to Exceptional Access Program Drugs for Ontarians Living Near Manitoba and Quebec Borders under the Ontario Drug Benefit Program
    – Questions and Answers
June 4

*Please refer to entry posted on July 5, 2021 for the latest updated EO Notice on Eligibility + Billing that was effective on July 5, 2021.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date June 4, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date June 4, 2021)
    – Updated: Questions and Answers for Pharmacists
    – Updated: Questions and Answers for Patients

June 4

Executive Officer Notice: The Ontario Drug Programs Reference Manual, Revision #3
    – Ontario Drug Programs Reference Manual

May 31

*Please refer to entry posted on July 5, 2021 for the latest updated EO Notice on Eligibility + Billing that was effective on July 5, 2021.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date May 31, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date May 31, 2021)
    – Updated: Questions and Answers for Pharmacists
    – Updated: Questions and Answers for Patients

May 31 Updated Executive Officer Notice: Specimen Collection for COVID-19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies: Eligibility Criteria
May 23

*Please refer to entry posted on July 5, 2021 for the latest updated EO Notice on Eligibility + Billing that was effective on July 5, 2021.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date May 23, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date May 13, 2021) (FYI: No change from May 13 posting)
    –Updated: Questions and Answers for Pharmacists (FYI: No change from May 13 posting)
    – Updated: Questions and Answers for Patients (FYI: No change from May 13 posting)

May 21 Executive Officer Notice: Administration of Second Doses for Individuals who received First Dose of AstraZeneca / COVISHIELD COVID-19 Vaccines in Ontario Pharmacies
    – Questions and Answers for Patients
May 18

*Please refer to entry posted on July 5, 2021 for the latest updated EO Notice on Eligibility + Billing that was effective on July 5, 2021.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date May 13, 2021) (FYI: No change from May 13 posting)
    – Updated: Questions and Answers for Pharmacists (FYI: No change from May 13 posting)
    – Updated: Questions and Answers for Patients (FYI: No change from May 13 posting)

May 13

*Please refer to entry posted on July 5, 2021 for the latest updated EO Notice on Eligibility + Billing that was effective on July 5, 2021.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date May 13, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date May 13, 2021)
    – Updated: Questions and Answers for Pharmacists
    – Updated: Questions and Answers for Patients

May 11 Executive Officer Notice: Pause of the Administration of First Doses of Publicly Funded AstraZeneca / COVISHIELD COVID-19 Vaccines in Ontario Pharmacies
May 11 Executive Officer Notice: Updated Income Eligibility Thresholds for the Seniors Co-Payment Program under the Ontario Drug Benefit Program
    – Questions and Answers for Pharmacists
    – Questions and Answers for Patients
May 6

*Please refer to entry posted on July 5, 2021 for the latest updated EO Notice on Eligibility + Billing that was effective on July 5, 2021.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date May 6, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing

    – Questions and Answers for Pharmacists (FYI: No change from April 30 posting)
    – Questions and Answers for Patients (FYI: No change from April 19 posting)

May 5 Notice from the Executive Officer: Funding of enoxaparin under the Ontario Drug Benefit Program
    – Frequently Asked Questions
April 30

*Please refer to entry posted on July 5, 2021 for the latest updated EO Notice on Eligibility + Billing that was effective on July 5, 2021.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date April 30, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date April 30, 2021)
    – Updated Questions and Answers for Pharmacists
    – Questions and Answers for Patients (FYI: No change from April 19 posting)

April 23 * Please refer to entry posted on May 31 2021 for the latest updated EO Notice on Eligibility and Investigation Numbers

Updated Executive Officer Notice: Specimen Collection for COVID-19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies: Eligibility Criteria

April 19

*Please refer to entry posted on July 5, 2021 for the latest updated EO Notice on Eligibility + Billing that was effective on July 5, 2021.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date April 19, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date April 19, 2021)
    – Questions and Answers for Pharmacists
    – Questions and Answers for Patients

April 16 Executive Officer Notice of interim change to Extemporaneous Preparations Policy for Anti-infectives for Post-Hospital Use
April 15 Executive Officer Notice: Proposed Legislative and Regulatory Amendments - Dissolution of the Citizens’ Council and the Pharmacy Council under the Ontario Drug Benefit Act
April 7

* Please refer to entry posted on April 23, 2021 for the latest updated EO Notice on Eligibility and Investigation Numbers

Updated: Executive Officer Notice: Specimen Collection for COVID-19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies: Eligibility Criteria

April 1

*Please refer to entry posted on July 5, 2021 for the latest updated EO Notice on Eligibility + Billing that was effective on July 5, 2021.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date April 1, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date April 1, 2021)
    – Questions and Answers for Pharmacists
    – Questions and Answers for Patients

March 26

Executive Officer Notice: Proposal to update the Income Eligibility Thresholds for the Seniors Co-Payment Program under the Ontario Drug Benefit Program

March 25

*Please refer to entry posted on July 5, 2021 for the latest updated EO Notice on Eligibility + Billing that was effective on July 5, 2021.

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date March 22, 2021)

Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date March 22, 2021)
    – Questions and Answers for Pharmacists
    – Questions and Answers for Patients

March 25

Notice from the Executive Officer: Funding of Adalimumab under the Ontario Drug Benefit Program
    – Frequently Asked Questions

March 18

Notice from the Executive Officer: The Ontario Drug Programs Reference Manual, Revision #2

Notice from the Executive Officer: Regulatory Amendments relating to Recordkeeping Requirements for Pharmacies and Dispensing Physicians under the Ontario Drug Benefit Program
    – Questions and Answers
March 17

*Please refer to entry posted on July 5, 2021 for the latest updated EO Notice on Eligibility + Billing that was effective on July 5, 2021.

Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies
    – Questions and Answers for Pharmacists
    – Questions and Answers for Patients

March 16 Executive Officer Notice: Update of the OPDP At A Glance Report
March 5

* Please refer to entry posted on April 23, 2021 for the latest updated EO Notice on Eligibility and Investigation Numbers

UpdatedExecutive Officer Notice: Specimen Collection for COVID-19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies: Eligibility Criteria

March 5 Notice from the Executive Officer: Reconciliation Adjustment Percentages for 2021/22 to Improve the Value of Pharmacy Payments
February 19

* Please refer to entry posted on April 23, 2021 for the latest updated EO Notice on Eligibility and Investigation Numbers

Executive Officer Notice: Expansion of Specimen Collection for COVID-19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies (Eligibility and Investigation Numbers)
(Effective February 19, 2021)

Updated Executive Officer Notice: Expansion of Specimen Collection for COVID-19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies (Billing, Pharmacy Record Documentation)
(Effective February 19, 2021)
Updated Questions and Answers for Pharmacists
Updated Questions and Answers for Patients

January 25 Notice from the Executive Officer: Funding of Insulin Lispro under the Ontario Drug Benefit Program
    – Questions and Answers
January 15 Executive Officer Notice: Amendments to Policy for Pharmacy Payments under the Long-Term Care Home Capitation Funding Model, 2020
    – Questions and Answers for Pharmacists
2020
December 18 Executive Officer Notice: Administering the Flu Vaccine to Children Age 2 and older under the Universal Influenza Immunization Program 2020/21
December 18 Executive Officer Notice: Funding of Avsola (Infliximab) under the Ontario Drug Benefit Program
    – Questions and Answers
December 14 Executive Officer Notice: Update to Drug Benefit Claim - Submission/Reversal Forms
    – Questions and Answers
December 14 Executive Officer Notice: Update to Special Authorization – Allergen (SAA) Form
December 8

* Please refer to entry posted on April 23 2021 for the latest updated EO Notice on Eligibility and Investigation Numbers
** Please refer to entry posted on February 19, 2021 for the latest updated EO Notice on Billing and Pharmacy / Patient Qs and As

Executive Officer Notice: Update - Expansion of Specimen Collection for COVID-19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies
(Effective December 11, 2020)
    – Questions and Answers for Pharmacists
    – Questions and Answers for Patients

December 7 Executive Officer Notice: Fluarix influenza vaccine injection added to the Universal Influenza Immunization Program 2020/21 for Pharmacists Administering Flu Vaccines
November 30 Executive Officer Notice: FluMist Nasal Spray added to the Universal Influenza Immunization Program 2020/21 for Pharmacists Administering Flu Vaccines
November 20 Executive Officer Notice: Forgery Notification Alerts in the Health Network System (HNS), including the Narcotics Monitoring System (NMS)
    – Questions and Answers
November 5

* Please refer to entry posted on April 23 2021 for the latest updated EO Notice on Eligibility and Investigation Numbers
** Please refer to entry posted on February 19, 2021 for the latest updated EO Notice on Billing and Pharmacy / Patient Qs and As

Notice from the Executive Officer: Expansion of Specimen Collection for COVID-19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies
    – Questions and Answers for Pharmacists
    – Questions and Answers for Patients

October 26 Notice from the Executive Officer: Updates to Pharmacists Administering Flu Vaccine to patients without a Health card number
October 26 Notice from the Executive Officer: Reminder to pharmacies on extensions to expiry dates on Ontario health card numbers
October 22 Notice from the Executive Officer: Proposal to Streamline Recordkeeping Requirements for Pharmacies and Dispensing Physicians under the Ontario Drug Benefit Program
October 21 Executive Officer Notice: Funding of Emerade™ (Epinephrine Auto-Injector) through the Allergen Program
October 6 Executive Officer Notice: Proposal to Improve Access to Exceptional Access Program Drugs for Ontarians Living Near Manitoba and Quebec Borders

October 2 Notice from the Executive Officer: Pharmacist administration of publicly funded influenza vaccines and claims submission using the Health Network System
    – Frequently Asked Questions

August 24 Executive Officer Notice: Funding of Riximyo (rituximab) and Ruxience (rituximab) under the Ontario Drug Benefit Program
    – Frequently Asked Questions
August 5 Executive Officer Notice: Funding of Allerject® (Epinephrine Auto-Injector) through the Allergen Program
July 30 Executive Officer Notice: Inspections Return to Work
June 12 Executive Officer Notice: Removal of the 30-days' Supply Dispensing Limit Recommendation
    – Frequently Asked Questions
May 21 Notice from the Executive Officer: Funding of Teva UK-labelled Salamol CFC-Free (Salbutamol Sulfate) Inhaler as a Temporary Benefit on the Ontario Drug Benefit (ODB) Formulary.
May 13 Notice from the Executive Officer: Regulatory Amendments to Ontario Drug Benefit Program Co-payments
    – Frequently Asked Questions

May 13 Notice from the Executive Officer: Changes to the Trillium Drug Program in Response to COVID-19
    – Frequently Asked Questions
May 1 Notice from the Executive Officer: Proposed Regulatory Amendments to Ontario Drug Benefit (ODB) Program Co-payments and Dispensing Fees
April 23 Notice from the Executive Officer: Brand Reference Price Regulations Amendment
April 23 Notice from the Executive Officer: Drug Submissions for Ontario Drug Benefit (ODB) Program during the COVID-19 Public Health Emergency
April 15 Executive Officer Notice: Updated Quarterly Report Back Form for the Ontario Naloxone Program for Pharmacies (ONPP)
    – Questions and Answers for the Updated QRBF
    – Quarterly Report Back Form
April 15 Notice: Ontario Drug Benefit Program and Exceptional Access Program Changes during the COVID-19 Public Health Emergency
April 7 Notice from the Executive Officer: Regulation Amendments to Private Label Products and Brand Reference Pricing Rules
April 1 Notice: Extending Submission Period for Electronic Drug Claim Reversals AND The Ontario Drug Programs Reference Manual, Revision #1
    – Frequently Asked Questions
April 1 Notice: Policy for Methadone Maintenance Treatment Reimbursement under the Ontario Drug Benefit Program
    – Frequently Asked Questions for Pharmacists
March 30 Notice from the Executive Officer: Proposed amendments to the effective date of changes to allow Private Label Products to be funded under the Ontario Drug Benefit (ODB) Program and Designated as Interchangeable Products on the ODB Formulary
March 30 Notice from the Executive Officer: Proposed Regulatory Amendments on Rules for Determining Brand Reference Prices
March 30 Notice from the Executive Officer: Funding of Truxima (rituximab) under the Ontario Drug Benefit Program
    – Frequently Asked Questions
March 23 Notice: Updates to the Ontario Guidelines for Drug Submission and Evaluation
March 20 Notice: Ontario Drug Benefit (ODB) Program Changes and Guidance for Dispensers during the COVID-19 Public Health Emergency
March 2 Notice: Reconciliation Adjustment Percentages for 2020/21 to Improve the Value of Pharmacy Payments
2019
December 23 Notice: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee Act to reduce Administrative Burden to Drug Manufacturers and Pharmacies
December 23 Notice: Updates to the Ontario Guidelines for Drug Submission and Evaluation Notice
December 16 Notice: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act and Regulation 935 made under the Drug Interchangeability and Dispensing Fee Act to reduce restrictions on Private Label Products and Ordinary Commercial Term benefits
December 16 Notice: Policy for Pharmacy Payments under the Long-Term Care Home Capitation Funding Model, 2020
    – Frequently Asked Questions
    – Key Facts for Pharmacists
    – Key Facts for Patients and Families
    – Attestation Notice of Change in LTC Home Primary Pharmacy Service Provider Form

December 16 Notice: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Improve the Value of Pharmacy Payments
    – Frequently Asked Questions for Pharmacists
October 28 Notice: Proposal to Improve the Value of Pharmacy Payments
October 28 Notice from the Executive Officer: Proposal to Reduce Administrative Burden to Drug Manufacturers and Pharmacies
October 18 Notice from the Executive Officer: Pharmacist administration of publicly funded influenza vaccines and claims submission using the Health Network System
    – Frequently Asked Questions
October 1 Notice from the Executive Officer: Updates to the Drug Evaluation Process for Biosimilar Products
September 12 Notice from the Executive Officer: Funding Flash Glucose Monitoring System Through the Ontario Drug Benefit Program
July 31 Notice from the Executive Officer: Updated Funding of Erelzi (etanercept) under the Ontario Drug Benefit Program
    – Frequently Asked Questions
July 24 Notice from the Executive Officer Submission Requirements: Flash GlucoseMonitoring (FGM)
July 4 Notice from the Executive Officer: Updates to the Ontario Guidelines for Drug Submission and Evaluation
June 4 Notice from the Executive Officer: Change to the Health Network System Subscription Agreement for Pharmacy Operators
April 26 Notice from the Executive Officer: Proposals to Establish More Efficient Pharmacy Reimbursement Policies
March 13 Notice from the Executive Officer: Buprenorphine/Naloxone (Suboxone® and generics) Reimbursement Reminder under the Ontario Drug Benefit Program
February 27 Notice from the Executive Officer: Amendment to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to make changes to Ontario Drug Benefit Program coverage for children and youth aged 24 years and under (OHIP+)
    – Frequently Asked Questions for Patients
     – Frequently Asked Questions for Pharmacists
February 13 Notice from the Executive Officer: Extension of the Temporary Facilitated Access Mechanism (Rheumatology) until March 31, 2019)
February 1 Notice from the Executive Officer: Administrative Monetary Penalty Issued for Acceptance of Rebates
  – Rebate Order
January 2 Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to make changes to Ontario Drug Benefit Program coverage for children and youth aged 24 years and under (OHIP+)
2018
December 31 Notice from the Executive Officer: Interim Extension of the Temporary Facilitated Access Mechanism (Rheumatology)
December 4 Notice from the Executive Officer: Completion of Strengthening Pharmacy Payment Management
October 29 Notice from the Executive Officer: Proposed Amendments to Regulations under the Ontario Drug Benefit Act and the Drug Interchangeability and Dispensing Fee Act relating to Private Label Products
October 4 Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccines and Claims Submission using the Health Network System
  – Frequently Asked Questions
September 25 Notice from the Executive Officer: Update on Claims Submission for Valved Holding Chambers through the Ontario Drug Benefit Program
September 20 Notice from the Executive Officer: Funding of Renflexis (infliximab) under the Ontario Drug Benefit Program
  – Frequently Asked Questions
September 20 Notice from the Executive Officer: Funding of Glatect (glatiramer acetate) under the Ontario Drug Benefit Program
  – Frequently Asked Questions
September 10
(Updated October 11)
Notice from the Executive Officer: Availability and Funding of AUVI-Q® (Epinephrine Auto-Injectors) as a Result of the Shortage of EpiPen® Products.
August 14 Notice from the Executive Officer: Claim Submission/Reversal and Special Authorization (Allergen) forms
July 30 Notice from the Executive Officer: Update on OHIP+
May 4 Notice from the Executive Officer: Refreshed ODB Report Card
May 1 Notice from the Executive Officer: Update Regarding Strengthening Pharmacy Payment Management

March 29
(Updated
October 12)

Notice from the Executive Officer: Changes in the Way Pharmacies Verify Eligibility for Individuals Receiving Social Assistance
  – Identification you can use to get health services
  – How to Register Your Pharmacy for the SAV Portal
  – SAV Portal Info Sheet

March 21
(Updated April 27)

* Please also refer to entry April 15 under 2020 for new information on the Ontario Naloxone Program for Pharmacies (ONPP) in regards to the Quarterly Report Back Form.

Notice from the Executive Officer: Funding of Naloxone Nasal Spray through the ONPP and Updates to the Existing Program
  – Frequently Asked Questions
  – Instructional Insert

March 8 Notice from the Executive Officer: Funding of Naloxone Nasal Spray through the ONPP
  – Frequently Asked Questions
March 5 Notice from the Executive Officer: Pan-Canadian Select Molecule Price Initiative for Generic Drugs
March 2 Notice from the Executive Officer: Ontario Drug Benefit Act Regulatory Amendment to Support the Ontario Basic Income Pilot (OBIP)
  – Frequently Asked Questions
February 21 Notice from the Executive Officer: Funding of Hepatitis B Drugs under the Ontario Drug Benefit Program
  – Frequently Asked Questions
February 8 Notice from the Executive Officer: Addition of Nurse Practitioners to the Palliative Care Facilitated Access (PCFA) Mechanism
January 24 Notice from the Executive Officer: Edition 43 of the Ontario Drug Benefit Formulary
January 16 Notice from the Executive Officer: Ontario Drug Benefit Act Proposed Regulatory Amendments to Align Maximum Days’ Supply of Prescriptions Dispensed for Ontario Works Recipients 25 years of Age and Older
January 10 Notice from the Executive Officer: Ontario Drug Benefit Act Proposed Regulatory Amendment to Support the Ontario Basic Income Pilot (OBIP)
  – Frequently Asked Questions
2017
December 22 Notice from the Executive Officer: Drug Submission – Submission Requirements: Valved Holding Chambers (VHCs)
December 21 Notice from the Executive Officer: Funding Valved-Holding Chambers through the Ontario Drug Benefit Program
December 14 Notice from the Executive Officer: Funding of Erelzi (etanercept) under the Ontario Drug Benefit Program
  – Frequently Asked Questions
December 14 Notice from the Executive Officer: Temporary Facilitated Access Mechanism (Rheumatology) for Ontario Drug Benefit Recipients aged 24 years and under
December 1 Notice from the Executive Officer: Removal of the Special Authorization (Allergen) Form for Pharmacy Dispensing of Epinephrine Auto-Injectors for Ontario Drug Benefit recipients
November 17 Addendum: Notice from the Executive Officer: Addition of Agriflu® to the Universal Influenza Immunization Program
October 13 Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccines and Claims Submission using the Health Network System for the 2017/2018 Influenza Immunization Season
  – Frequently Asked Questions
September 21 Notice from the Executive Officer: Notice from the Executive Officer: Promoting Compliance with the Existing Limited Use Criteria for the Fentanyl Transdermal Patch
  – Frequently Asked Questions
September 21 Notice from the Executive Officer: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Support the Homes for Special Care Modernization Initiative
September 1 Notice from the Executive Officer: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Strengthen Pharmacy Payment Management
September 1 Notice from the Executive Officer: Amendment to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Create and Implement OHIP+: Children and Youth Pharmacare
August 23 Notice from the Executive Officer: Notice from the Executive Officer: Thyroid (Desiccated Thyroid) Delisting
August 3 Notice from the Executive Officer: Funding of Mifepristone/Misoprostol (Mifegymiso) (updated December 7, 2017)
  – Frequently Asked Questions for Health Care Providers (updated December 7, 2017)
  – Frequently Asked Questions for Patients (updated December 7, 2017)
August 1 Notice from the Executive Officer: Funding of filgrastim under the Ontario Drug Benefit Program
  – Frequently Asked Questions
July 21 Notice from the Executive Officer: Funding of Brenzys (etanercept) under the Ontario Drug Benefit Program
  – Frequently Asked Questions
July 11 Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Create and Implement OHIP+: Children and Youth Pharmacare Program
July 7 Notice from the Executive Officer: Ontario Drug Benefit Act, Legislative amendments to recognize the role of Nurse Practitioners in requesting Exceptional Access Program products and prescribing Listed Substances (Bill 87)
  – Frequently Asked Questions for Health Care Providers
June 29 Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Strengthen Pharmacy Payment Management
March 16 Notice from the Executive Officer: Pan-Canadian Select Molecule Price Initiative for Generic Drugs
February 21 Notice from the Executive Officer: Funding of Hepatitis C drug products under the Ontario Drug Benefit Program
  – Frequently Asked Questions for Health Care Providers
  – Frequently Asked Questions for Patients
January 27 Notice from the Executive Officer: Updated Reminder Regarding Delisting of High-Strength Long-Acting Opioids under the Ontario Drug Benefit (ODB) Program
2016
December 21 Notice from the Executive Officer: Funding of Grastofil (filgrastim) under the Ontario Drug Benefit program
  – Frequently Asked Questions
December 1 Notice from the Executive Officer: Funding of Inflectra under the Ontario Drug Benefit Program
  – Frequently Asked Questions
November 30 Notice from the Executive Officer: Update Regarding Palliative Care Access to High-Strength Long-Acting Opioids under the Ontario Drug Benefit (ODB) Program
October 24 Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccines for 2016-2017 Season and Claims Submission using the Health Network System
  – Frequently Asked Questions
October 07 Notice from the Executive Officer: Application of Generic Substitution to the Exceptional Access Program
 – Frequently Asked Questions for Patients
 – Frequently Asked Questions for Pharmacists
 – Frequently Asked Questions for Physicians
September 26 Notice from the Executive Officer: Regulation amendments to optimize appropriate access to unlisted, non-Formulary drug products and further streamline submission requirements for generic drug products
September 16 Notice from the Executive Officer: Regulation to support the Safeguarding our Communities Act, 2015 (Patch for Patch Return Program)
  – Frequently Asked Questions for Prescribers and Pharmacists
September 16 Notice from the Executive Officer: Drug Submission – Ontario Guidelines for Drug Submission and Evaluation 2016
September 02 Notice from the Executive Officer: Changes in the Way Social Assistance Clients Access Drug Coverage

  – Updated Drug Eligibility Card Pharmacy Information Sheet 
  – Updated User Guide
  – Updated ODB Cannot be confirmed via HNS
  – Updated ODB Cannot be confirmed via HNS– Accessible version
  – Drug Eligibility Pharmacy Quick Reference Guide
  – Drug Eligibility Pharmacy Questions and Answers

For Social Assistance Clients

  – Drug Eligibility Card Client Information Sheet
 – Social Assistance Client Cheque Insert - Aug./Sept. version
 – Social Assistance Client Cheque Insert - Oct./Nov. version

August 17 (Updated April 27)

* Please refer to entry March 21 under 2018 for current information on the Ontario Naloxone Program for Pharmacies (ONPP). The materials below are available below for reference purposes.
* Please also refer to entry April 15 under 2020 for new information in regards to the Quarterly Report Back Form.

Notice from the Executive Officer: Reminder - Ontario Naloxone Program for Pharmacies (ONPP)

Notice from the Executive Officer: Ontario Naloxone Program for Pharmacies (ONPP)

  – Frequently Asked Questions for Pharmacists

August 15 Notice from the Executive Officer: Reimbursement and Claims Submissions using the Health Network System relating to Drugs for Medical Assistance in Dying
  – Frequently Asked Questions for Pharmacists
July 20 Notice from the Executive Officer: Changes to the Ontario Drug Benefit (ODB) Program Funding of Opioid Medications
  – Frequently Asked Questions for Pharmacists
July 4 Notice from the Executive Officer: MedsCheck Program Enhancements
June 10 Notice from the Executive Officer: Health Network System (HNS) Changes to Support the Maximizing Quantity Dispensed for Chronic-Use Medications Initiative
  – Frequently Asked Questions
June 1 Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee Act to optimize appropriate access to unlisted, non-Formulary drug products and further streamline submission requirements for generic drug products
June 1 Notice from the Executive Officer: Proposed Regulation under the Safeguarding our Communities Act (Patch for Patch Return Policy)
April 15 Notice from the Executive Officer: Regulation Amendments to Expand Access to the Seniors’ Co-Payment Program under the Ontario Drug Benefit (ODB) Program
March 22 Executive Officer Notice Drug Submission – Information Bulletin
March 15 Notice from the Executive Officer: Pan-Canadian Competitive Value Price Initiative for Generic Drugs
March 11 Notice from the Executive Officer: Funding of Inflectra under the Ontario Drug Benefit Program
  – Frequently Asked Questions
February 29 Notice from the Executive Officer:Proposal to amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act to update cost-sharing arrangements for non-low income seniors under the Ontario Drug Benefit (ODB) program
2015
November 23 Notice from the Executive Officer: New Blood Glucose Test Strip Reimbursement Policy
November 13 Notice from the Executive Officer: Claims submission for prescriptions with drug costs over $10,000
  – Frequently Asked Questions
October 13 Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccine for 2015-2016 Season and Claims Submission using the Health Network System
  – Frequently Asked Questions updated October 2015
September 18 Notice from the Executive Officer: Regulation Amendments to Streamline Submission Requirements for Certain Generic Products seeking Interchangeability Designations on the Ontario Drug Benefit Formulary
September 18 Notice from the Executive Officer: Regulation Amendments to Support Sustainability and Access for the Ontario Public Drug Programs
September 18 Notice from the Executive Officer: Supporting Sustainability and Access for the Ontario Drug Benefit Program
  – Questions & Answers for Pharmacists
  – Questions & Answers for Physicians
  – Questions & Answers for Patients
  – Chronic-use Medications List by Generic Name
July 23 Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee Act
  – Questions & Answers for Patients
May 20 Notice from the Executive Officer: Tiered Generic Pricing Framework
March 10 Notice from the Executive Officer: Pan-Canadian Competitive Value Price Initiative for Generic Drugs
2014
November 5, 2014 Notice from the Executive Officer: Proposed Regulation Amendments to Establish a Pricing Framework for Certain Generic Products on the Ontario Drug Benefit (ODB) Formulary
English | French
October 10 Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccine for 2014-2015 Season and Claims Submission using the Health Network System
English | French
  – Frequently Asked Questions updated November 21, 2014
    English | French
March 11 Notice from the Executive Officer: Reminder of the Upcoming Changes for April 1, 2014   [PDF]
March 10 Notice from the Executive Officer: Pan-Canadian Competitive Value Price Initiative for Generic Drugs   [PDF]
2013
November 28 Notice from the Executive Officer: Edition 42 of the Ontario Drug Benefit Formulary   [PDF]
November 26 Notice from the Executive Officer: Accuracy in Claims Submissions   [PDF]
October 4 Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccine for 2013-2014 Season and Claims Submission using the Health Network System  
english | french
September 17 Blood Glucose Test Strip Reimbursement Update   [PDF]
July 11 Notice to Pharmacies - Contacting the ODB Help Desk   [PDF]
July 8 Notice from the Executive Officer: Blood Glucose Test Strip Reimbursement Policy   [PDF]
english | french
June 11 Notice from the Executive Officer: Professional Allowances Reporting Template for Drug Manufacturers [Excel]
March 7 Notice from the Executive Officer: Reminder of the Upcoming Changes for April 1, 2013
March 4 Notice from the Executive Officer: Pan-Canadian Competitive Value Price Initiative for Generic Drugs
February 20 Important Notice from the Executive Officer: Proper Submission of Prescriber Identification to the Health Network System (HNS) and Narcotics Monitoring System (NMS)   [PDF]
February 13 Notice from the Executive Officer: Professional Allowances Reporting Template for Drug Manufacturers   [Excel]
February 4 Notice from the Executive Officer: FINAL Reminder Regarding the Funding Status of Oxycodone Controlled Release Tablet – OxyNEO   [PDF]
January 24 Notice from the Executive Officer: New Regulatory Requirements for Long-Acting Oxycodone Drug Products   [PDF]
January 15 Notice from the Executive Officer: Assignment of ON Numbers to Health Network System/Ontario Drug Benefit Accounts
2012
December 20 Notice from the Executive Officer: Expanded Scope of Practice and Accuracy in Claims Submission   [PDF]
December 12 Delisting of Aliskiren (Rasilez®) from the ODB Formulary - Questions & Answers
November 28 Important notice regarding the prescribing and dispensing of Oxycodone CR.
english | french
November 23 Proposed Regulation Amendments to Set Additional Conditions for Submission Requirements of Long-Acting Oxycodone Drug Products
english | french
October 10 Notice to Pharmacies – Contacting the Help Desk   [PDF]
October 9 Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccine and Claims Submission using the Health Network System; 2012-2013 Influenza Season
 - Fact Sheet
 - Q & As
October 4 Notice from the Executive Officer: Important Reminder Regarding the Funding Status of Oxycodone Controlled Release Tablet - OxyNEO   [PDF]
September 27 Notice from the Executive Officer: Changes to the Transition Fee Payments under the Ontario Drug Benefit (ODB) Program
September 24 Important Notice from the Executive Officer: Proper Submissions to the Narcotics Monitoring System (NMS)   [PDF]
August 20 Notice from the Executive Officer. Re: Professional Allowances Reporting Template for Drug Manufacturers   [Excel]
August 15 Proposed Regulation Amendment to Reduce the Transition Fee Payments under the Ontario Drug Benefit (ODB) Program
May 8 Important Notice from the Executive Officer: Submission of Monitored Drug Information to the Narcotics Monitoring System
April 12 Notice from the Executive officer. Re: Implementation of the Narcotics Monitoring System (NMS)
english | french
March 16 Notice from the Executive Officer. Re: Upcoming Changes for April 1, 2012
February 27 Notice from the Executive Officer. Re: Pharmaceutical Opinion Program
February 17 Notice from the Executive Officer: RE: Important Notice Regarding Change in Funding Status of Oxycodone Controlled Release Tablet – (Discontinuation of OxyContin and Introduction of OxyNEO)
english | french
February 6 Notice from the Executive Officer. Re: Professional Allowances Reporting Template for Drug Manufacturers
2011
December 6 Notice from the Executive officer. Re: Prescriber ID Requirements for Claims Submitted on the Health Network System (HNS)
November 30 Notice from the Executive Officer. Re: Additional Clarification Regarding the Narcotics Legislation
October 27 Notice from the Executive Officer. Re: Additional Questions on the Narcotics Legislation
english | french
October 14 Important Notice to Health Care Providers on the New Requirements under the Narcotics Safety and Awareness Act, 2010
October 14 Public Notice Regarding the Ministry of Health and Long-Term Care's ("ministry") Collection, Use and Disclosure of Information under the Narcotics Safety and Awareness Act, 2010
english | french
September 9 Suspension of Ontario Drug Benefit (ODB) Billing Accounts
August 31 Notice from the Executive Officer. Re: MedsCheck Program Standardization and system Requirements
August 31 Notice from the Executive Officer. Re: Pharmaceutical Opinion Program
August 29 Notice from the Executive Officer. Re: Pharmacy Smoking Cessation Program
August 22 Notice from the Executive Officer. Re: Expanding Professional Pharmacy Services for September 1, 2011
July 28 Notice from the Executive Officer. Re: Professional Allowances Reporting Template for Drug Manufacturers
June 10 Notice from the Executive Officer. Re: Extension of Transition Fee Payments and Conditions for Payment of Dispensing Fees for Remote Dispensing Location under the Ontario Public Drug Programs
May 24 Clarification to the Notice from the Executive Officer. Re: Lucentis – Change in Status to Limited Use (April 1, 2011)
April 7 Notice from the Executive Officer. Re: New Regulation under the Optometry Act, 1991
April 4 Notice from the Executive Officer. Re: Request for Qualification (RFQ) for Acquirer Host Network Services
April 1 Notice from the Executive Officer. Re: EAP criteria change for rosiglitazone (Avandia)
April 1 Notice from the Executive Officer. Re: Lucentis - Change in Status to Limited Use
March 29 Notice from the Executive Officer. Re: Implementation of the first stage of expanded services
March 23 Notice from the Executive Officer. Re: Expanding Professional Pharmacy Services for April 1, 2011
March 23 Notice from the Executive Officer. Re: Increase in Dispensing Fees, Effective April 1, 2011
March 18 Notice from the Executive Officer. Re: New Regulation under the Drug and Pharmacies Regulation Act (DPRA)
February 28 Notice from the Executive Officer. Re: Professional Allowances Reporting Template for Drug Manufacturers
February 09 Notice from the Executive Officer. Re: Narcotics Monitoring System Questions and Answers
2010
December 6 Notice from the Executive Officer. Re: Formulary Listing for Enalapril Maleate
October 19 Q & As for Change in Listing Status for Gabapentin
September 30 Notice from the Executive Officer. Re: Pharmacy ONE Mail System Registration - Reminder Notice
September 8 Notice from the Executive Officer. RE: MedsCheck Program Expanded Services Launched September 13, 2010
August 26 Notice from the Executive Officer: Change in Status to Limited Use (Humira and Enbrel) & New Limited Use Listing (Stelara) 
 - Q & As for Change in Listing Status for Humira, Enbrel, and Stelara
August 23 Notice from the Executive Officer. RE: Expanding Professional Pharmacy Services Working Group
July 13 Notice from the Executive Officer:
Reporting Framework for Professional Allowances
June 08 Notice from Ontario Public Drug Programs
Re: Clarification of Digoxin Listings
January 25 Notice from the Executive Officer: Reporting Framework for Professional Allowances
2009
July 17 Policy to Acquire Medications for Treatment of Tuberculosis
- Dear Pharmacist Letter. Communiqué from the Public Health Division, MOHLTC
July 15 Notice from the Executive Officer: Reporting Framework for Professional Allowances
May 6 Notice from the Executive Officer: Change of Funding Status Rosiglitazone (Avandia®) and Pioglitazone (Actos® and Generics) 
 - Q&As for TZD Funding Status Change
May 6 Notice from the Executive Officer: Expanded Limited Use Criteria for Clopidogrel (Plavix)
 - Q&As for Clopidogrel Expanded LU Criteria
March 3 Notice from the Executive Officer - MedsCheck Adjustment Payment to Pharmacies Ending on April 1, 2009
February 23 Notice from the Executive Officer: Ongoing Transparency Initiative: Public Posting of Drug Submission Status - Updates
February 4 Notice from the Executive Officer: Reminder – Professional Allowance Reporting: July 1, 2008 to December 31, 2008
January 13 Notice from the Executive Officer: Academic Detailing Program
 - Q&As for Academic Detailing Program
2008
December 19 Notice from the Executive Officer: Health Network System (HNS) Enhancements to Support the Conditions for Payment of Dispensing Fees under the Ontario Drug Benefit (ODB) Program
December 17 Notice from the Executive Officer: Renewal of the Health Network System (HNS) Subscription Agreement
December 1 Notice from the Executive Officer: Enhancements to Health Network System to Support the Conditions for Payment of Dispensing Fees under the Ontario Drug Benefit (ODB) Program
December 1 Notice from the Executive Officer: Announcement of Changes to the Formulary respecting Enalapril Maleate
November 17 Notice from the Executive Officer: Telephone Request Service for Exceptional Access Program
 - Q&As for External Stakeholders
October 29 Executive Officer Notice: Completing the New Health Network System (HNS) Agreement
October 27 Executive Officer Notice: Price Increase Requests
October 20 Notice of Termination and Replacement of Agreement: Ontario Public Drug Programs Subscription Agreement
October 3 Notice from the Executive Officer: Public Consultation to Review the definition of Professional Allowance and the Codes of Conduct
October 2 Notice from the Executive Officer: Notice of Termination and Replacement of Agreement: Ontario Public Drug Programs Subscription Agreement
September 30 Notice From Executive Officer: Implementation Plan To Review The Definition Of Professional Allowance And The Code Of Conduct
September 19 Notice from the Executive Officer: Notice Of Cancellation Of Call For Application For Ranitidine Hydrochloride
August 26 Notice from the Executive Officer: Drug Submissions Requirement - Revised Letter of Consent
August 22 Notice from the Executive Officer Reminder - Professional Allowance Reporting
August 5 Notice from the Executive Officer: Claims for ZANTAC® under the Ontario Drug Benefit Program
July 28 Conditions for Payment of Dispensing Fees under the Ontario Drug Benefit (ODB) Program  
 - Questions and Answers
July 18 Notice from the Executive Officer: Reporting Framework for Professional Allowances
July 16 Notice from the Executive Officer: Competitive Agreements Q&As
July 8 Notice from the Executive Officer: Ontario Public Drug Programs Competitive Agreement  
 - Briefing for Stakeholders
June 4 Notice from the Executive Officer: Manufacturer Review of Transparency Bulletin  
May 29 Notice from the Executive Officer: Pricing of Products Reimbursed Under the Exceptional Access Program (EAP)
May 16 Notice from Executive Officer
May 16 Notice from Executive Officer: Limited Use (LU) Process Changes 
May 13 Notice from Executive Officer: Ongoing Transparency Initiative - Public Posting of Drug Submission Status.  
April 17 Notice from the Executive Officer: Lucentis Questions and Answers  
April 15 Recruitment for Pharmacy Council Members, letter from the Executive Officer  
March 6 Notice from the Executive Officer: Reporting Framework for Professional Allowances
January 30 2008 BBS Notice from the Executive Officer: MedsCheck, Adjustment Payment to Pharmacies - a Reminder
2007
November 15 Notice from the Executive Officer, BBS Introducing the "Follow-up" MedsCheck, effective November 30, 2007
November 15 Recruitment for Pharmacy Council Members, letter from the Executive Officer
November 13 Notice from the Executive Officer: Reporting Framework for Professional Allowances
October 19 Notice from the Executive Officer: Reporting Framework for Professional Allowances
October 1 Notice to Manufacturers ­ Submission Requirements for Generic Drug Products
October 4
(BBS Nº.7079)
Notice from the Executive Officer: Lead Time Between the Formulary Update and Effective Date
September 14 (BBS Nº.7071)
Notice from the Executive Officer: Reporting Framework for Professional Allowances
July Letter to Pharmacists from the Executive Officer: MedsCheck Update
July 13 Notice to Pharmacists: MedsCheck Update
May 29 (BBS Nº.7029)
MedsCheck Update
May 8 (BBS Nº.7025)
Notice to Pharmacists from Executive Officer: Follow up to April 5, 2007 Notice
April 1 Letter to Pharmacists from the Executive Officer: MedsCheck
February 21 (BBS Nº.7009)
Notice from the Executive Officer: Reporting Framework for Professional Allowances
2006
December 18 (BBS Nº.6086)
Notice from the Executive Officer: Amending Regulations under ODBA and DIDFA
September 28 Notice to Pharmacists: Regulation Changes made to the Ontario Drug Benefit Act (ODBA) and the Drug Interchangeability and Dispensing Fee Act (DIDFA)
April 13 (BBS Nº.6029)
Notice to Pharmacists: Bill 102, Transparent Drug System for Patients Act

For More Information

Call ServiceOntario, Infoline at:
1–866–532–3161 (Toll–free)
In Toronto, (416) 314–5518
TTY 1–800–387–5559.
In Toronto, TTY (416)327–4282
Hours of operation: Monday to Friday, 8:30am – 5:00pm

 
  • Connect With Us
Facebook Twitter YouTube RSS